Substance / Medication

Cyclosporine

Overview

Active Ingredient
cyclosporine
RxNorm CUI
3008
Labeler: Mayne Pharma Inc.Updated: 2026-02-12T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Boxed WARNINGS (See alsoabove) Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking cyclosporine [MODIFIED]. Cyclosporine, the

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

164 trials linked to this intervention

164
Total Trials
41
Recruiting
61
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis.
Zhang Yin, Chen Hong, Zhang Huimin et al. · Eur J Med Res · 2025
PMID: 41351015Meta-AnalysisFull text (PMC)
Efficacy and safety of cyclosporine in colitis: An updated meta-analysis of randomized control trials (1998 to 2024).
Mehreen Aqsa, Batool Faiza, Awan Uzma Azeem et al. · Inflammopharmacology · 2025
PMID: 41065960Meta-Analysis
Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis.
Pitre Tyler, Gurupatham Samuel, Desai Kairavi et al. · BMJ Open Respir Res · 2025
PMID: 40216413Meta-AnalysisFull text (PMC)
Adjuvant Use of Topical 0.05% Cyclosporine A in Primary Pterygium Recurrence Rate: A Systematic Review and Meta-analysis.
Aleksander-Ivanov Yuri, Cheidde Lidia, Veiga Davi Marçola et al. · Am J Ophthalmol · 2025
PMID: 40562088Meta-Analysis
Cyclosporine in uveitis: a game changer or a risky choice? A systematic review and meta-analysis of its efficacy and safety.
Chen Kai Yang, Chan Hoi-Chun, Chan Chi Ming · Br J Ophthalmol · 2025
PMID: 40812793Meta-Analysis
Population pharmacokinetics of cyclosporine A in hematopoietic stem cell transplant recipients: A systematic review.
Yang Yunyun, Zhu Yiping, Xia Lin et al. · Eur J Pharm Sci · 2025
PMID: 39214318Meta-Analysis
Evaluating the efficacy of nano-cyclosporine A in mice model of ulcerative colitis: a meta-analysis.
Mehreen Aqsa, Batool Faiza, Awan Uzma Azeem et al. · Naunyn Schmiedebergs Arch Pharmacol · 2025
PMID: 39873716Meta-Analysis
Safety and Efficacy of 0.1% Cyclosporine Solutions in Dry Eye Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Aleksander-Ivanov Yuri, Amaral Dillan Cunha, Cheidde Lidia et al. · J Ocul Pharmacol Ther · 2025
PMID: 39929477Meta-Analysis
Clinical features and effects of cyclosporine in the treatment of psoriasis: a systemic review and meta-analysis.
Li Zaibing, Pei Baoqiang, Lei Tianbing et al. · Arch Dermatol Res · 2024
PMID: 39460805Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ciclosporin (substance)
SNOMED CT
387467008
UMLS CUI
C0010592
RxNorm CUI
3008
Labeler
Mayne Pharma Inc.

Clinical Data

This intervention maps to 14 entities in the Healos knowledge graph.

6
Conditions
4
Biomarkers
2
Specialists
0
Symptoms
164
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.